Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$70.45 USD
-1.32 (-1.84%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $70.44 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Corcept Therapeutics Incorporated has a market cap of $7.56B, which represents its share price of $71.77 multiplied by its outstanding shares number of 105.37M. As a mid-cap company, CORT's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CORT 70.45 -1.32(-1.84%)
Will CORT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar?
Other News for CORT
CORT: Today's Analyst Rating Update and Price Target Adjustment | CORT Stock News
Corcept Therapeutics (CORT) Target Price Revised by Piper Sandler Analyst
Corcept Therapeutics (CORT) Price Target Lowered, Buy Rating Maintained
ClearBridge Small Cap Fund Q2 2025 Commentary
Piper Sandler Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News